The medications approved by the Food and Drug Administration (FDA) for treating Huntington’s disease chorea are Xenazine (tetrabenazine), Ingrezza (valbenazine) and Austedo (deuterabenazine).

Data Reinforce the Clinically Meaningful Impact of INGREZZA in Adults with Huntington's Disease Chorea Findings Presented at the 2025 American Association of Neuroscience Nurses Neuroscience Advanced ...

People with movement disorders can have a difficult time doing day-to-day activities, which could impact their independence. This can affect how people see themselves and affect their social life.

ROCKVILLE, Md., Aug. 15 -- The FDA has approved tetrabenazine (Xenazine), the first agent for chorea in Huntington's disease, the involuntary jerky movements that are a hallmark of the condition. "For ...

Please provide your email address to receive an email when new articles are posted on . The new once-daily tablet strength doses are 30 mg, 36 mg, 42 mg and 48 mg. Symptom improvement in tardive ...

"Most people with Huntington's disease experience chorea, one of the most debilitating symptoms of the condition that can interfere with motor coordination, gait, swallowing and speech," said Sanjay ...

Huntington’s disease (HD) is a rare inherited condition that gets progressively worse, affecting movement, thinking, mood, and behavior. For people living with HD, the “simple” tasks and activities of ...

Amy Aungst, center right, organizes walks in Cape Henlopen, Delaware, to raise awareness about Huntington’s disease, a rare condition that is estimated to affect about 30,000 or more U.S. adults.